"Since its inception, the company has undergone rapid growth, systematically adding the capabilities needed to successfully manufacture, develop and commercialise T-cell therapies.

Autolus is committed to bringing life-changing treatments to cancer patients by reprogramming their own T-cells to more effectively combat the treatment of haematological malignancies and solid tumours."